文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

药物治疗对系统性右心室患者心力衰竭发生率的影响

Effect of medical treatment on heart failure incidence in patients with a systemic right ventricle.
PubMed 文献 · Heart · 2021-05-06

本研究在两大三级中心观察359例系统性右心室患者,中位随访7.1年,采用倾向评分加权控制混杂,评估ACE抑制剂或ARB对心衰发生和死亡的影响。结果显示,ACEi/ARB治疗与心衰发生率或死亡率无显著关联,尽管该人群存在神经激素激活,仍无证据支持其获益。

要点

  • 在系统性右心室患者中,ACEi或ARB治疗未显著降低心衰发生率或死亡率。
  • 该人群心衰事件发生率为11.8%,死亡率为3.6%,心脏移植率为2.1%。
  • 研究采用倾向评分加权多因素Cox分析控制混杂,仍未显示ACEi/ARB的获益。

核心结论

  • 在系统性右心室患者中,ACEi或ARB治疗与较低的心衰发生率或死亡率无显著关联。

研究设计与样本

  • 观察性研究,纳入2007年1月至2018年9月在两所三级中心随访的359例系统性右心室患者,采用倾向评分加权控制混杂。

主要发现

  • 138例(38%)接受ACEi或ARB治疗,79例(22%)存在中重度系统性右心室功能障碍。
  • 多因素Cox分析结合倾向评分加权显示,ACEi或ARB治疗与心衰发生率或死亡率无显著关联。

临床怎么用

  • 对于系统性右心室患者,不应仅基于神经激素激活的证据常规使用ACEi或ARB来预防心衰或死亡。

局限性

  • 本研究为观察性设计,可能存在残余混杂,且样本来自两所三级中心,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, clinical trials have been underpowered to demonstrate a benefit from ACE inhibitors (ACEis) or angiotensin II receptor blockers (ARBs) in preventing systemic right ventricle (sRV) failure and disease progression in patients with transposition of the great arteries (TGA). This observational study aimed to estimate the effect of ACEi and ARB on heart failure (HF) incidence and mortality in a large population of patients with an sRV. METHODS: Data on all patients with an sRV under active follow-up at two tertiary centres between January 2007 and September 2018 were studied. The effect of ACEi and ARB on the incidence of HF and mortality was estimated using a propensity score weighting approach to control confounding. RESULTS: Among the 359 patients with an sRV (32.2 (IQR 26.4-38.3) years, 59.3% male, 66% complete TGA with atrial switch repair and 34% congenitally corrected TGA), 79 (22%) had a moderate to severe sRV dysfunction and 138 (38%) were treated with ACEi or ARB. Fourteen (3.6%) patients died, 8 (2.1%) underwent heart transplantation and 46 (11.8%) had a new HF event over a median follow-up of 7.1 (IQR 4.0-9.4) years. On multivariate Cox analysis with adjustment using propensity score weighting approaches, ACEi or ARBs treatment was not significantly associated with a lower HF incidence or mortality in patients with an sRV. CONCLUSIONS: Despite significant neurohormonal activation described in patients with an sRV, there is still no evidence of a beneficial effect of ACEi or ARB on morbidity and mortality in this population.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Ladouceur M, Segura de la Cal T, Gaye B, et al. Effect of medical treatment on heart failure incidence in patients with a systemic right ventricle. Heart. 2021. PMID: 33958396. doi:10.1136/heartjnl-2020-318787

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。